{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"The maximum tolerated dose (MTD) was defined as the highest dose level at which no more than 1 of 6 patients experienced a dose-limiting toxicity (DLT) within the first 28-day cycle. If no more than 1 of these 6 patients experienced a DLT within the first 28-day cycle, then the last dose level enrolled to meet these criteria was identified as the recommended dose for the Phase 2 segment of the study.","groups":[{"description":"Participants received either 160 mg ACY-1215 once per day (Dose Level 1) or 160 mg ACY-1215 twice per day (Dose Level 3) and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Phase 1b - ACY-1215"}],"paramType":"NUMBER","populationDescription":"All treated participants in Phase 1b. Prespecified to be reported as combined for Phase 1b only.","reportingStatus":"POSTED","timeFrame":"From first dose until the end of Phase 1b (up to a maximum of approximately 50 weeks).","title":"Maximum Tolerated Dose (MTD) of ACY-1215- Phase 1b","type":"PRIMARY","unitOfMeasure":"mg/day"}